Serotonin exhibits various cardiovascular effects and evidence of its role in various cardiovascular disorders is emerging. Serotonin levels in whole blood and the platelet serotonin uptake were significantly increased in patients with heart failure compared to control subjects. However, the intraplatelet serotonin content was not significantly different in the two groups. We conclude that serotonin is involved in the syndrome of heart failure both directly and indirectly through its action on cardiac contractility, heart rate, preload, and afterload.
NityanandSTekwaniBLChandraMKinetics of serotonin in platelets in essential hypertension. Life Sci1989; 46: 367–72.
5.
JafriSMChandraNDhawanSFactors influencing platelet serotonin uptake in essential hypertension. Int J Cardiol1992; 34: 327–33.
6.
ChandraMChandraN. Serotonergic mechanisms in hypertension. Int J Cardiol1993; 42: 189–96.
7.
ChandraMChandraNGuptaSPlatelet serotonin kinetics in acute myocardial infarction before and after thrombolysis. Ind J Exp Biol1993; 31: 999–1001.
8.
WillersonJTGolinoPEioltJSpecific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation1989; 80: 198–205.
9.
HalpernAKuhnPHShaftelHERaynaud's disease, Raynaud's phenomenon, and serotonin. Angiology1960; 11: 151–67.
10.
ShoemarkerRGXioaYDBaxWA5-Hydroxytryptamine stimulates human isolated atrium but not ventricle. Eur J Pharmacol1993; 230: 103–5.
11.
BradleyPBEngelGFeniukProposal for the classification and nomenclature of functional receptors for 5-Hydroxytryptamine. Neuropharmacology1986; 25: 563–76.
12.
LevineRJ. Serotonin and the carcinoid syndrome. Histamine and mastocytosis. In: BondyPKRosenbergLE, editors. Duncan's diseases of metabolism: endocrinology. 7th edPhiladelphia: WB Saunders, 1974:1651–84.
13.
CulleyWJSandersRNMertzETJollyDH. Effect of a tryptophan-deficient diet on brain serotonin and plasma tryptophan level. Proc Soc Exp Biol Med1963; 113: 645–8.
14.
HoyerDClarkeDEFozardJRVII International Union of Pharmacology classification of receptors for 5-hydroxytryptamine. Pharmacol Rev1993; 46: 157–203.
15.
PeroutkaSJHowellTA. The molecular evolution of G protein coupled receptors: focus on 5-hydroxytryptamine receptors. Neuropharmacology1994; 33: 319–24.
16.
PalaciosJMWaeberCHoyerDMengodG. Distribution of serotonin receptors. Ann NY Acad Sci1990; 600: 36–52.
17.
KaumannAJSandersL. 5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT4 receptors in human atrium: facilitation by chronic beta-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol1994; 349: 331–7.
18.
SandersLKaumannAJ. A 5-HT4-like receptor in human left atrium. Naunyn Schmiedebergs Arch Pharmacol1992; 345: 382–6.
19.
FrishmanWHHuberfeldSOkinSSerotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol1995; 35: 541–72.
20.
CollisMGDeMeyCVanhouttePM. Renal vascular reactivity in the young spontaneously hypertensive rat. Hypertension1979; 2: 45–52.
21.
VanhouttePM. Peripheral serotonergic receptors and hypertension. In: VanhouttePM, editor. Serotonin and the cardiovascular system. New York: Raven Press, 1985:123–33.
22.
SteinJMLindRWJohnsonAK. Central serotonergic influences on renal electrolyte and water excretion. Neuropharmacology1987; 26: 1685–92.
23.
SteardoLIovionM. Vasopressin release after enhanced serotonergic transmission is not due to activation of the peripheral renin-antiotensin system. Brain Res1986; 382: 145–8.
24.
BalmentRJBrimbleMJForslingMLMusabayaneCT. Natriuretic response of the rat to plasma concentrations of arginine vasopressin within the physiological range. J Physiol1984; 352: 517–26.
25.
BentegBGGohenJKunosGKunosIV. Dissociation of 5-HT effects on myocardial contractivity and cyclic AMP accumulation. Br J Pharmacol1974; 50: 581–5.
26.
BuccinoARCovellJWSonnenblickEHBraunwallE. Effect of serotonin on the contractivity state of myocardium. Am J Physiol1967; 213: 483–6.
SaxenaPRVillalonCM. 5-Hydroxytryptamine: a chameleon in the heart. Trends Pharmacol Sci1991; 12: 22–7.
29.
JanssenPAJ. 5-HT2 receptor blockade to study serotonin-induced pathology. Trends Pharmacol Sci1983; 4: l98–206.
30.
KoekWJacksonAColpaertFC. Behavioural pharmacology of antagonists at 5-HT2/5-HT1C-receptors. Neurosci Biobehav Rev1992; 16: 95–105.
31.
CohnJNArchibuldDGZiescheSEffect of vasodilator therapy on mortality in chronic congestive heart failure: result of Veterans administration study. New Engl J Med1986; 3141: 1547–52.
32.
SoleMJShumAVanloonGR. Serotonin metabolism in normal and failing hamster heart. Circ Res1979; 45: 629–34.
33.
ReidJVO. Trial of tryptophan prophylaxis in patients liable to African cardiomyopathy. S Afr Med J1970; 44: 732–5.
34.
ChandraMGuptaVJohriAKSerotonergic mechanisms in heart failure. Indian Heart J1994; 46: 153–6.
35.
DemoulinJCBerlholetMSovarnagneD5-HT2 blockade in the treatment of HF: a preliminary study. Lancet1981; 1: 1186–8.
36.
MajidPAMorrisWMSoleMJ. Haemodynamic and neurohormonal effects of ketanserin, a 5-HT2 receptor antagonist in patients with congestive heart failure. Can J Cardiol1987; 3: 70–4.
